<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-35898" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hydroquinone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schwartz</surname>
            <given-names>Chelsea</given-names>
          </name>
          <aff>The Christ Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jan</surname>
            <given-names>Arif</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chelsea Schwartz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arif Jan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-35898.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Hydroquinone cream is the standard depigmentation or skin lightening agent. Clinically it is used to treat areas of dyschromia, such as in melasma, chloasma, solar lentigines, freckles, and post-inflammatory hyperpigmentation. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, and monitoring of hydroquinone, so providers can direct patient therapy to optimal outcomes in conditions where it is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the indications for using hydroquinone therapy.</p></list-item><list-item><p>Describe the mechanism of action of hydroquinone.</p></list-item><list-item><p>Summarize the potential adverse events associated with hydroquinone.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance improved outcomes using hydroquinone when indicated.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35898&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35898">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-35898.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Hydroquinone cream is the standard depigmentation or skin lightening agent. Clinically it is used to treat areas of dyschromia, such as in:</p>
        <list list-type="bullet">
          <list-item>
            <p>Melasma</p>
          </list-item>
          <list-item>
            <p>Chloasma</p>
          </list-item>
          <list-item>
            <p>Solar lentigines</p>
          </list-item>
          <list-item>
            <p>Freckles</p>
          </list-item>
          <list-item>
            <p>Post-inflammatory hyperpigmentation</p>
          </list-item>
        </list>
        <p>Its most common use is in patients with post-inflammatory hyperpigmentation and melasma.</p>
        <p>
<bold>Post-inflammatory Hyperpigmentation</bold>
</p>
        <p>Postinflammatory hyperpigmentation results from cutaneous inflammation, causing increased melanin production. Common causes of postinflammatory hyperpigmentation are acne vulgaris, eczematous dermatoses, contact dermatitis, psoriasis, lichen planus, and burns.<xref ref-type="bibr" rid="article-35898.r1">[1]</xref> The most common cause of hyperpigmentation results from photodamage from sunlight exposure.<xref ref-type="bibr" rid="article-35898.r2">[2]</xref> Inflammation increases the release and oxidation of arachidonic acid to prostaglandins and leukotrienes, resulting in increased melanin production.<xref ref-type="bibr" rid="article-35898.r3">[3]</xref> Hydroquinone is used to treat postinflammatory hyperpigmentation along with photoprotection. Improvement with hydroquinone occurs over several weeks to months.<xref ref-type="bibr" rid="article-35898.r4">[4]</xref></p>
        <p>
<bold>Melasma</bold>
</p>
        <p>Melasma is an acquired hyperpigmentation condition and presents on sun-exposed areas of the face, commonly the forehead, cheeks, and chin.<xref ref-type="bibr" rid="article-35898.r5">[5]</xref> It presents as symmetrically distributed pigmented macules and patches.<xref ref-type="bibr" rid="article-35898.r6">[6]</xref> Factors that play a role in the pathogenesis of melasma are darker skin, UV radiation, hormones, genetics, and antiepileptic medications. Exposure to UV radiation is the main factor in pathogenesis as UV radiation increases alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone levels, which increases the proliferation of melanocytes.<xref ref-type="bibr" rid="article-35898.r7">[7]</xref> Also, at the dermal layer, increased expression of stem cells of fibroblasts and tyrosine kinase receptor c-kit is present in melasma lesions. Also noted in lesions are upregulation of vascular endothelial growth factor (VEGF), Wnt, and reactive oxygen species seen after UV-induced dermal inflammation. Vascularization and melanocyte hyperreactivity results from this UV-induced inflammation leading to increased melanin production and hyperpigmentation. Patients who are pregnant or use oral contraceptives are also at risk because the expression of estrogen receptors seems to rise in melasma lesions as well.<xref ref-type="bibr" rid="article-35898.r8">[8]</xref><xref ref-type="bibr" rid="article-35898.r6">[6]</xref> Estrogen also induces the release of melanocyte-stimulating hormone (MSH), which stimulates tyrosinase leading to increased melanin production. For this reason, melasma occurs more frequently in females vs. males.<xref ref-type="bibr" rid="article-35898.r6">[6]</xref>&#x000a0;Treatment is similar to postinflammatory hyperpigmentation, with photoprotection and hydroquinone being the first line.</p>
        <p>Photoprotection is a significant key in maximal benefit from hydroquinone use. Melanocytes become stimulated from UVB, UVA, and even visible light leading to pigmentation. Therefore, broad-spectrum sunscreens are a recommended strategy.<xref ref-type="bibr" rid="article-35898.r6">[6]</xref></p>
        <p>Hydroquinone is not FDA approved due to its unknown safety profile. It is banned in the EU, Australia, and Japan.</p>
      </sec>
      <sec id="article-35898.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Hydroquinone acts as a skin depigmentation agent by inhibiting melanin synthesis. It inhibits the conversion of L-3,4- dihydroxyphenylalanine (L-DOPA) to melanin by inhibiting tyrosinase due to its structural similarity to an analog of melanin precursors.<xref ref-type="bibr" rid="article-35898.r6">[6]</xref></p>
        <p>
<bold>The Pathway of Melanin Synthesis</bold>
<xref ref-type="bibr" rid="article-35898.r9">[9]</xref>
</p>
        <list list-type="order">
          <list-item>
            <p>Hydroxylation of L-phenylalanine to L-tyrosine</p>
          </list-item>
          <list-item>
            <p>Tyrosinase hydroxylates L-tyrosine to 3,4 L-dihydroxyphenylalanine (L-DOPA)</p>
          </list-item>
          <list-item>
            <p>L-DOPA oxidized to dopaquinone</p>
          </list-item>
          <list-item>
            <p>Production of eumelanin and pheomelanin resulting in black to brown and yellow to red color of skin</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-35898.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Hydroquinone is only used topically as a depigmentation agent. A thin layer is applied with fingertips and rubbed into the face (or other affected areas) 1 to 2 times a day&#x000a0;for 3 to 6 months. If there are no results after 2 to 3 months, hydroquinone should be discontinued. It is essential to evenly apply hydroquinone over the entire face to prevent uneven pigmentation and use concurrently with sunscreen to protect from damaging UV light, which increases pigmentation. &#x000a0;Physicians recommended stopping treatment after this time for a few months before restarting to decrease the risk of side effects. It can also be applied during weekends only or three times a week for more extended maintenance therapy with minimal complications.<xref ref-type="bibr" rid="article-35898.r6">[6]</xref></p>
        <p>Hydroquinone is available in 2% over the counter or as 4% prescribed.<xref ref-type="bibr" rid="article-35898.r2">[2]</xref>&#x000a0;It comes in the following dose forms: cream, emulsion, gel, or solution.</p>
        <p>Multiple studies have shown that maximum results occur when using hydroquinone as a combination therapy with a retinoid and corticosteroid. The most widely used triple combination cream is composed of hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%.<xref ref-type="bibr" rid="article-35898.r6">[6]</xref> Use in combination with other agents requires a prescription by a dermatologist.</p>
        <p>Results vary among each patient.</p>
        <p>About 35% to 45% of hydroquinone is absorbed systemically after topical use.<xref ref-type="bibr" rid="article-35898.r10">[10]</xref></p>
      </sec>
      <sec id="article-35898.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Effects Include</bold>
<xref ref-type="bibr" rid="article-35898.r11">[11]</xref>
<xref ref-type="bibr" rid="article-35898.r6">[6]</xref>
<xref ref-type="bibr" rid="article-35898.r2">[2]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Irritation</p>
          </list-item>
          <list-item>
            <p>Allergic contact dermatitis</p>
          </list-item>
          <list-item>
            <p>Erythema</p>
          </list-item>
          <list-item>
            <p>Inflammation</p>
          </list-item>
          <list-item>
            <p>Xeroderma</p>
          </list-item>
          <list-item>
            <p>Stinging</p>
          </list-item>
          <list-item>
            <p>Rarely ochronosis - ochronosis is a blue-black or gray-blue discoloration; it is rare and more commonly seen in patients that use a high concentration of hydroquinone for a long period on large areas of the body.</p>
          </list-item>
        </list>
        <p>Studies also suggest that hydroquinone can falsely elevate capillary glucose when measured with a glucometer.<xref ref-type="bibr" rid="article-35898.r12">[12]</xref></p>
        <p>There has been no confirmation regarding concerns that hydroquinone cream is carcinogenic either in clinical practice or human research.<xref ref-type="bibr" rid="article-35898.r6">[6]</xref></p>
      </sec>
      <sec id="article-35898.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <list list-type="bullet">
          <list-item>
            <p>Allergic reaction or hypersensitivity hydroquinone&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sun exposure</p>
          </list-item>
          <list-item>
            <p>The use of this drug requires caution&#x000a0;with other medications that cause photosensitivity.</p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy Category C</bold>
</p>
        <p>About 35 to 45% of the topical hydroquinone&#x000a0;dose is absorbed systemically. Current studies have not shown an increased risk of malformations or adverse effects in pregnant women, but it is recommended to minimize exposure due to the substantial absorption.<xref ref-type="bibr" rid="article-35898.r10">[10]</xref> The safety of breastfeeding mothers and children remains unestablished, and as such, breastfeeding females should avoid this drug.</p>
      </sec>
      <sec id="article-35898.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitor for any hypersensitivity or long-term irritation, in which case the medication should be discontinued. Also, in rare cases, ochronosis&#x000a0;develops; the patient should stop using hydroquinone and consult a clinician.</p>
      </sec>
      <sec id="article-35898.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>No significant toxicity has been found with the topical use of the hydroquinone cream.</p>
        <p>Some studies report malignancies in animals treated for an extended period with large oral doses.<xref ref-type="bibr" rid="article-35898.r2">[2]</xref></p>
        <p>
<bold>Hydroquinone in the Environment</bold>
</p>
        <p>In the environment, hydroquinone is a chemical and can be toxic in human and industrial activities by promoting the generation of reactive oxygen species, oxidative stress, and hence the potential for DNA damage. It is a major benzene metabolite and is known to be hepatotoxic and carcinogenic in these settings. Some studies suggest it can promote tumor cell growth and suppress the immune response. It is used in photography and is present in dyes, paints, varnishes oils, and motor fuels. In its oxidized form, it is more toxic and less degradable. It demonstrates high toxicity to aquatic organisms and rodents and may induce leukemia, renal tubular cell tumor, and liver cancer. It has also been found to influence immune cell responses and causes an increase in an allergic reaction by increasing interleukin-4 production and immunoglobulin E levels.<xref ref-type="bibr" rid="article-35898.r13">[13]</xref></p>
      </sec>
      <sec id="article-35898.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The interprofessional health care team, such as physicians, nurses, and pharmacists, play an essential role in monitoring patients on hydroquinone. It is important to monitor patients to ensure that they only use the medication as prescribed for no more than 5 to 6 months to limit side effects. Nursing staff can play a significant role in monitoring the patient and evaluating compliance, as it is important to follow instructions for the medication application, its frequency, keep a watchful eye for any adverse effect, which should be clearly explained to the patient. Patients should be instructed to cease using the medication if any irritation, hypersensitivity, or allergic reaction occurs. Pharmacists can review the use and adverse events when dispensing the drug, and monitor when the patient comes in for refills, alerting the prescribing clinician regarding any concerns. The rare, yet most potentially harmful, side effect of&#x000a0;ochronosis needs to be explained to patients using hydroquinone, and they should be instructed to discontinue this medication immediately if this occurs. A collaborative interprofessional team approach to hydroquinone therapy will guide outcomes most effectively. [Level 5]</p>
      </sec>
      <sec id="article-35898.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=35898&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=35898">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/35898/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=35898">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-35898.s11">
        <title>References</title>
        <ref id="article-35898.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epstein</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Postinflammatory hyperpigmentation.</article-title>
            <source>Clin Dermatol</source>
            <year>1989</year>
            <season>Apr-Jun</season>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>55</fpage>
            <page-range>55-65</page-range>
            <pub-id pub-id-type="pmid">2667741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stephens</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Babcock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bucay</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gotz</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Split-face Evaluation of a Multi-ingredient Brightening Foam Versus a Reference Control in Women with Photodamaged Facial Skin.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>24</fpage>
            <page-range>24-28</page-range>
            <pub-id pub-id-type="pmid">30519376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tagami</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms for hyperpigmentation in postinflammatory pigmentation, urticaria pigmentosa and sunburn.</article-title>
            <source>Dermatologica</source>
            <year>1989</year>
            <volume>179 Suppl 1</volume>
            <fpage>49</fpage>
            <page-range>49-53</page-range>
            <pub-id pub-id-type="pmid">2550287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsambas</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Stratigos</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Depigmenting and bleaching agents: coping with hyperpigmentation.</article-title>
            <source>Clin Dermatol</source>
            <year>2001</year>
            <season>Jul-Aug</season>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>483</fpage>
            <page-range>483-8</page-range>
            <pub-id pub-id-type="pmid">11535393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kauh</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Zachian</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Melasma.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>1999</year>
            <volume>455</volume>
            <fpage>491</fpage>
            <page-range>491-9</page-range>
            <pub-id pub-id-type="pmid">10599387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sofen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prado</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Emer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.</article-title>
            <source>Skin Therapy Lett</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">27224897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmoud</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Ruvolo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hexsel</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kollias</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Hamzavi</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>Impact of long-wavelength UVA and visible light on melanocompetent skin.</article-title>
            <source>J Invest Dermatol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>130</volume>
            <issue>8</issue>
            <fpage>2092</fpage>
            <page-range>2092-7</page-range>
            <pub-id pub-id-type="pmid">20410914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Estrogen receptor expression in melasma: results from facial skin of affected patients.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2008</year>
            <month>May</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>463</fpage>
            <page-range>463-5</page-range>
            <pub-id pub-id-type="pmid">18505139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Speeckaert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Van Gele</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Speeckaert</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Geel</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The biology of hyperpigmentation syndromes.</article-title>
            <source>Pigment Cell Melanoma Res</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>512</fpage>
            <page-range>512-24</page-range>
            <pub-id pub-id-type="pmid">24612852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozzo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chua-Gocheco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Einarson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety of skin care products during pregnancy.</article-title>
            <source>Can Fam Physician</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>665</fpage>
            <page-range>665-7</page-range>
            <pub-id pub-id-type="pmid">21673209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rendon</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Barkovic</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>1435</fpage>
            <page-range>1435-1441</page-range>
            <pub-id pub-id-type="pmid">28095558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choukem</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Efie</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Djiogue</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaze</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Mboue-Djieka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Boudjeko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dongo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gautier</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kengne</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Effects of hydroquinone-containing creams on capillary glycemia before and after serial hand washings in Africans.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>e0202271</fpage>
            <pub-id pub-id-type="pmid">30153255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-35898.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Enguita</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Leit&#x000e3;o</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Hydroquinone: environmental pollution, toxicity, and microbial answers.</article-title>
            <source>Biomed Res Int</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>542168</fpage>
            <pub-id pub-id-type="pmid">23936816</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
